On September 24, 2014, a world-class group of scientists from biotech, pharma and academia will present the latest research findings and new technologies that are driving the design, discovery and development of new drugs – from small molecules and monoclonals to RNA therapeutics and gene-editing technologies.

The event is free and organized by the American Chemical Society (ACS) and ACS’s magazine C&EN news.

To register for free please follow this link.  Even if you can’t make the live lectures or the time zone is not convenient for you, all presentations will be archived and available on demand for three months.

You will even have the chance to “Walk the floor” in a virtual exhibition hall, participate in panel discussions and Q&A sessions and do live-chat with peers and vendors

Some of the talks that I find interesting:

Accurate Prediction of Ligand Binding Free Energies – MARK MURCKO, PhD (Disruptive Biomedical LLC)

Design of Protein Structures, Functions and Assemblies – DAVID BAKER, PhD (HHMI/Univ of Washington)

Site-directed ligand discovery for cryptic sites – MICHELLE ARKIN PhD (UCSF)

The Promises and Challenges of Next-Generation Therapeutics – GREG VERDINE, PhD (Warp Drive Bio)

Structure based Drug Design: G-protein coupled receptors using StaR tech – FIONA MARSHALL (Heptares)

Drug Repositioning in the Era of Personalized Medicine – CRAIG WEBB, PhD (NuMedii)

Panel Discussion:The Business of Biotech – LUKE TIMMERMAN, MATT HERPER, MANDY JACKSON

Exploiting cell death for drug discovery – BRENT STOCKWELL, PhD (HHMI/Columbia University)

The VCNDD: CNS Drug Discovery in Academia – CRAIG W. LINDSLEY, PhD (Vanderbilt Center – VCNDD)

Targeting Lysine Acetylation in Cancer – JAY BRADNER, MD (Dana Farber Cancer Institute)